Bright Minds Biosciences (DRUG) Operating Expenses (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Operating Expenses data on file, last reported at -$9.6 million in Q1 2026.

• Quarterly Operating Expenses fell 508.37% year-over-year to -$9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.1 million (down 199.7% YoY) and the FY2025 annual result came in at $10.0 million, up 381.22% from the prior year.
• Operating Expenses eased to -$9.6 million in Q1 2026, from -$6.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $16.8 million in Q3 2025 to a low of -$9.6 million in Q1 2026.
• A 5-year average of $755460.1 and a median of $951047.2 in 2023 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 2842.82% in 2025, down 18642.06% in 2025.
• Tracing DRUG's Operating Expenses over 5 years: stood at $1.1 million in 2022, then retreated by 15.2% to $951047.2 in 2023, then tumbled by 96.59% to $32422.2 in 2024, then tumbled by 18642.06% to -$6.0 million in 2025, then plunged by 59.5% to -$9.6 million in 2026.
• The last three Operating Expenses figures came in at -$9.6 million (Q1 2026), -$6.0 million (Q4 2025), and $16.8 million (Q3 2025), per Business Quant data.